MEDLAB ANNOUNCES FAVOURABLE INTERIM READOUT OF NANABIS™ REAL-WORLD EVIDENCE (RWE) MEDCARE STUDY
January 12, 2023 07:30 ET
|
Medlab Clinical Ltd
N=1,172 Australian pain patientsDatapoints collected from commencing NanaBis™ (baseline) up to month 1255% improvement in pain relief75% of patients reduced their opioid use31% Improvements in Quality...
Medlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in collaboration with University of NSW (UNSW) and Macquarie University (MQ) to fight COVID-19 future potential epidemics
January 14, 2022 09:59 ET
|
Medlab Clinical Ltd
NSW Government grant received on 23rd December 2021 to develop a “no-jab” vaccine solutionMedlab collaborates with UNSW and MQ University (two leading global academic and R&D institutions)This...
Nanocelle® Patent Granted in Usa
November 04, 2021 09:35 ET
|
Medlab Clinical Ltd
Medlab receives Granted Patent Protection for NanoCelle® in the USA by US Patent & Trademark Office (USPTO) SYDNEY, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX: MDC) is...
DEPRESSION PATENT FOR OROTATE APPROVED & GRANTED BY US PATENT OFFICE
October 11, 2021 10:40 ET
|
Medlab Clinical Ltd
SYDNEY, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical LTD (ASX:MDC) is pleased to announce the Orotate patent, specifically to addressing depression in United States of America has been granted....
NANOCELLE “ISSUE OF ALLOWANCE” BY US PATENT OFFICE
October 06, 2021 11:10 ET
|
Medlab Clinical Ltd
SYDNEY, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical LTD (ASX.MDC) is pleased to announce NanoCelle® the company’s proprietary delivery platform has been issued a “Notice of Allowance” by the...
US Patent Office issues Notice of Allowance status for NRGBiotic™ for treating, preventing, or Ameliorating depression or a Depressive disorder.
July 27, 2021 09:06 ET
|
Medlab Clinical Ltd
SYDNEY, July 27, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is very pleased to announce the United States Patent...